Alper Coskun

Dr. Alper Coskun

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
STSalih Tunbekici
Salih Tunbekici
HYHaydar Çağatay Yüksel
Haydar Çağatay Yüksel
CACaner Acar
Caner Acar
GŞGökhan Şahin
Gökhan Şahin
SOSeval Orman
Seval Orman
PGPınar Gürsoy
Pınar Gürsoy
Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.

24 December 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ECEce Celebi Coskun
Ece Celebi Coskun
ACAlper Coskun
Alper Coskun
ASAhmet Bilgehan Sahin
Ahmet Bilgehan Sahin
FLFatih Levent
Fatih Levent
ECEyup Coban
Eyup Coban
FAFahriye Vatansever Agca
Fahriye Vatansever Agca
Background: Immune checkpoint inhibitors (ICI) are generally associated with rare cardiac side effects, yet instances like myocarditis can be fatal. Therefore, detecting and managing left ventricular dysfunction early in ICI therapy is vital.Objectives: This study aims to evaluate whether left ventricular global longitudinal strain (LV GLS) is a predictor for early detection of cardiac dysfunction in patients receving ICI.Methods: This retrospective cohort study included 44 cancer patients who received ICI therapy and underwent pre- and post- treatment assessments of left ventricular ejection fraction (LVEF) and LV GLS between May 2022 and November 2023. Retrospective comparisons and evaluations were conducted on pre-treatment and 3-month interval LVEF and LV GLS measurements during the first year of treatment.Results: The median follow-up duration was 5.3 months (0.5-18.9). No statistically significant difference between baseline and subsequent time points was observed in LVEF and LV GLS values (p>0.05). At the 3-month evaluation, a notable decrease in LVEF and LV GLS was observed in two patients. One patient with reduced LVEF and LV GLS succumbed to myocarditis, and another experienced sudden death of unknown etiology. The other two patients had decreased LV GLS with normal LVEF. Subsequent follow-ups of the patients exhibiting decreased LV GLS alone revealed no further decline in LVEF or LV GLS.Conclusion: In our study, a reduction in LV GLS did not demonstrate a significant role in the early prediction of ICI-related myocarditis or cardiac dysfunction. Further validation through multicenter, large-scale, prospective studies with extended follow-up periods is needed to confirm these findings.

1 December 2025 in Frontiers in Clinical Diabetes and Healthcare
Verified
Journal Article
Open access
ACAlper Coskun
Alper Coskun
ACAslihan Calim
Aslihan Calim
ESEmre Sedar Saygili
Emre Sedar Saygili
TSTamer Sakaci
Tamer Sakaci
FOFeyza Yener Ozturk
Feyza Yener Ozturk
TBTaner Basturk
Taner Basturk
Objective: Diabetes mellitus (DM) is a prevalent chronic disease that can lead to severe microvascular complications. Among these, diabetic nephropathy (DN) remains a leading cause of end-stage renal disease worldwide. Glycemic variability, reflecting fluctuations in blood glucose, has been suggested as a potential predictor of DM complications. This study aimed to investigate whether visit-to-visit HbA1c variability contributes to the development and progression of DN in patients with DM. Methods: In this retrospective cohort study, 228 patients were selected from 2,000 individuals diagnosed with DM between January 2007 and December 2017. A total of 80 patients without DN at baseline (ODN) and 148 patients with DN at baseline (WDN) were included in the study. HbA1c was measured 2–4 times per year over 3–5 years. Mean, standard deviation (SD), and coefficient of variation (CV) of HbA1c were calculated. Annual urea, creatinine, and albumin/protein levels were recorded. Logistic regression identified independent risk factors. Results: DN developed in 47 (58.8%) patients in the ODN group, whereas progression occurred in 44 (29.7%) patients in the WDN group. In the ODN group, higher HbA1c mean, SD, CV, hypertension, and albuminuria were significantly associated with DN onset (p<0.05). Logistic regression analysis confirmed HbA1c variability and hypertension as independent predictors. No significant association was found between HbA1c variability and DN progression. Conclusions: Variability in HbA1c is linked to the onset of DN but not its progression. These findings highlight the need for strategies targeting glycemic stability in DM management. Larger, multicenter prospective studies are warranted to confirm these results.

14 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ACAlper Coskun
Alper Coskun
ECECE CELEBİ COSKUN
ECE CELEBİ COSKUN
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
FLFatih Levent
Fatih Levent
ECEyüp Coban
Eyüp Coban
TETürkkan Evrensel
Türkkan Evrensel
Background/Objectives: Immune checkpoint inhibitor (ICI)-associated cardiovascular adverse events are relatively uncommon; they can be life-threatening, particularly when involving malignant ventricular arrhythmias. Electrocardiographic markers such as P-wave dispersion (PWD), QT dispersion (QTd), T-peak to T-end (Tp-e) interval, and Tp-e/QT and Tp-e/QTc ratios have been linked to an elevated risk of both atrial and ventricular arrhythmias and sudden cardiac death across various cardiac conditions. Monitoring these parameters may aid in identifying the risk of arrhythmogenic events in cancer patients undergoing ICI therapy. Methods: This retrospective cohort study analyzed 42 patients with cancer who received ICI therapy and had serial 12-lead electrocardiograms (ECGs) performed at baseline and at three-month intervals during the first year of treatment, from May 2022 to November 2023. ECG parameters including PWD, QTd, Tp-e interval, and Tp-e/QT and Tp-e/QTc ratios were measured and compared between baseline and follow-up time points. Results: The median follow-up duration was 5.3 months (range: 0.5–18.9 months). No statistically significant differences were observed in any of the ECG parameters between baseline and subsequent measurements (p > 0.05). One patient developed atrial fibrillation during the third month of treatment. Additionally, one patient exhibited a left anterior fascicular block, and another experienced frequent ventricular extrasystoles. No malignant ventricular arrhythmias were reported throughout the study period. Conclusions: This study found no significant changes in electrocardiographic markers associated with arrhythmia risk during ICI treatment. Larger, multicenter, prospective studies with extended follow-up are warranted to further elucidate the cardiovascular safety profile of ICIs.

13 December 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SSSeda Sali
Seda Sali
CACandan Demiröz Abakay
Candan Demiröz Abakay
MSMürsel Sali
Mürsel Sali
HGHakan Güdücü
Hakan Güdücü
FÇFahri Güven Çakır
Fahri Güven Çakır
ECErdem Cubukcu
Erdem Cubukcu
Background and Objectives: Nasopharyngeal carcinoma (NPC) displays marked geographic and histopathological heterogeneity, and prognostic determinants in non-endemic regions remain incompletely defined. This study aimed to evaluate the impact of clinicopathological characteristics and treatment modalities on survival outcomes among patients with stage II–IVA NPC treated with curative intent at a single tertiary cancer center. Materials and Methods: A retrospective analysis was conducted on 81 consecutive patients with histologically confirmed NPC treated between 2000 and 2022. Demographic, clinical, and treatment parameters were extracted from institutional records. Survival outcomes—including disease-free survival (DFS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS)—were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic variables identified in univariate analysis were further assessed by multivariable Cox proportional hazards regression (Cox’s model). Results: The cohort included 59 men (72.8%) and 22 women (27.2%), with a median age of 50.8 years (range, 19–78). Most patients presented with locally advanced disease (T3–T4, 53.1%; N2, 60.5%; stage III–IVA, 87.7%). Non-keratinizing undifferentiated carcinoma (World Health Organization [WHO] type III) was the predominant histology (71.6%), followed by the non-keratinizing differentiated subtype (17.3%). Median DFS and OS were 94.6 and 139.4 months, respectively. According to the univariate analysis, histological subtypes and a family history of cancer were significantly associated with DFS, whereas comorbid systemic disease showed an unexpected association with longer DMFS. The multivariable Cox model identified the histological subtype as an independent predictor of disease recurrence (HR = 2.23, 95% CI: 1.00–4.94; p = 0.049). For OS, both histological subtype (HR = 2.40, 95% CI: 1.10–5.25; p = 0.029) and age at diagnosis (HR = 1.05, 95% CI: 1.02–1.09; p = 0.005) were independent adverse prognostic factors. Conclusions: In this long-term, single-center study from a non-endemic region, histological subtype emerged as the most powerful determinant of prognosis, significantly influencing both DFS and OS. Patients with non-keratinizing undifferentiated (WHO type III) carcinoma demonstrated superior outcomes compared with those with differentiated histology. Additionally, increasing age at diagnosis was independently associated with poorer OS. In contrast, inflammatory and nutritional biomarkers, the Pan-Immune–Inflammation Value (PIV) and the Prognostic Nutritional Index (PNI), showed no prognostic significance. These findings underscore the continued prognostic relevance of histopathologic classification and age and highlight the need for large-scale, standardized studies integrating Epstein–Barr virus (EBV) status and host-related factors in non-endemic NPC populations.

10 July 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAlper Coskun
Alper Coskun
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
SKSelva Kabul
Selva Kabul
MÇMuhammed Abdurrahman Çelik
Muhammed Abdurrahman Çelik
MSMürsel Sali
Mürsel Sali
IYIsmet Yavascaoğlu
Ismet Yavascaoğlu
Background and Objective: Bladder cancer (BC) is the ninth most common malignancy worldwide. Squamous cell carcinoma (SqCC), a rare histological variant, accounts for approximately 2–5% of all BC cases. Compared to urothelial carcinoma, the predominant subtype, research on SqCC remains limited and shows inconsistent findings regarding prognosis. This study aimed to compare survival outcomes between patients with SqCC and those with pure urothelial carcinoma (PUC). Methods: This retrospective, observational study analyzed pathology reports from 2549 transurethral resections of bladder tumors and 632 cystectomies performed at our institution between 1 December 2010 and 31 December 2023. Following pathological re-evaluation, 33 patients with SqCC and 132 with PUC were identified. After 1:3 propensity score matching, 20 patients with SqCC and 58 with PUC were included in the final analysis. Demographic, clinicopathological features, and survival outcomes were compared between groups. Results: The median follow-up was 2.31 years (range: 0.17–13.50). No significant differences in baseline demographic or clinical characteristics were observed, except for the type of surgery. Kaplan–Meier analysis demonstrated no significant differences in disease-free survival (DFS; p = 0.961) or overall survival (OS; p = 0.847) between SqCC and PUC groups. Multivariate Cox regression analysis identified T stage, nodal involvement, and adjuvant chemotherapy (CT) as independent predictors of DFS, while sex and metastasis at diagnosis were significant predictors of OS. Conclusion: Survival outcomes (DFS and OS) did not significantly differ between patients with SqCC and patients with PUC. Prognosis was more closely associated with disease stage at diagnosis, sex, and adjuvant CT. Further large-scale studies are warranted.